Indivior Announces First Half and Second Quarter 2020 Results
| Period to June 30th | Q2 2020 $m | Q2 2019 $m | % ∆ Actual FX | % ∆ Constant FX | H1 2020 $m | H1 2019 $m | % ∆ Actual FX | % ∆ Constant FX |
|---|---|---|---|---|---|---|---|---|
| Net Revenue | 150 | 215 | -30 | -30 | 303 | 454 | -33 | -33 |
| Operating Profit/(Loss) | 25 | 88 | -72 | -71 | (165) | 163 | NM | NM |
| Net Income/(Loss) | 18 | 75 | -76 | -75 | (145) | 141 | NM | NM |
| EPS (cents per share) | 2 | 10 | -80 | -75 | (20) | 19 | NM | NM |
| Adj. Operating Profit* | 24 | 89 | -73 | -72 | 26 | 191 | -86 | -87 |
| Adj. Net Income* | 17 | 76 | -78 | -77 | 14 | 165 | -92 | -92 |
| Adj. EPS* | 2 | 10 | -80 | -77 | 2 | 23 | -91 | -92 |
*Adjusted (Adj.) basis excludes the impact of exceptional items as referenced in Notes 3 and 4. NM: Not Meaningful.
Comment by Mark Crossley, CEO of Indivior PLC
“I am proud of the Group’s resilient performance through this unprecedented period brought about by the COVID-19 pandemic. Considering this backdrop, our first-half results were solid. We maintained a good cash buffer and we did so while helping to ensure the safety and wellbeing of our employees. I am particularly encouraged by the performance of SUBLOCADE® (buprenorphine extended-release) Injection through this period, as Q2 net revenue of $29m was unchanged versus Q1’s level. Furthermore, we came to a satisfactory agreement with the DOJ (subject to judicial approval) that allows us to focus our resources on pursuing our Vision and patient-focused growth strategy. In the short term, we continue to be impacted by the industry-wide reduction in new patient starts in the U.S. However, looking to the future, I am confident that our novel depot technologies, SUBLOCADE® and PERSERIS® (risperidone) extended release injection, have the power to transform lives and to drive a new era of growth.”
Read full report here.